{"product_id":"amicusrx-swot-analysis","title":"Amicus Therapeutics SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eElevate Your Analysis with the Complete SWOT Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eAmicus Therapeutics shows strong rare-disease expertise and a diversified pipeline but faces commercialization, reimbursement, and competitive risks that could pressure growth; strategic partnerships and proprietary platforms are key strengths to monitor. Purchase the complete SWOT analysis to gain a professionally written, editable report that supports investment and strategic decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOrphan-disease leadership\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAmicus leverages deep expertise in lysosomal storage and rare genetic disorders—Galafold (migalastat) is approved in the US, EU and Japan—supporting robust R\u0026amp;D and commercial execution. The orphan focus yields regulatory advantages (US orphan exclusivity 7 years, EU up to 10 years), pricing leverage and streamlined patient access. Concentrated medical need drives durable demand and strong clinician engagement, building credibility with regulators and key opinion leaders.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercialized therapies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAmicus’s commercialized therapy Galafold (migalastat), approved in over 40 countries since FDA approval in 2016, provides an established revenue base that de‑risks operations versus pure-play clinical biotechs. Published real-world registry and peer‑reviewed data through 2023 support clinical adoption and inform lifecycle management. Global distribution and patient‑support programs drive adherence and retention. Ongoing cash flow is being directed to pipeline programs and post‑marketing studies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrecision and genetic targeting\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMechanisms that correct underlying genetic defects, exemplified by Amicus's pharmacological chaperone migalastat (Galafold), deliver differentiated clinical benefit versus symptom-only therapies and are approved in more than 40 countries. Companion diagnostics and genotype-guided prescribing improve responder identification, concentrating benefit in validated subpopulations. This enhances payer health-economic value propositions by reducing ineffective treatment exposure and supports defensible niches with high switching costs for entrants.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and market access know-how\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAmicus leverages experience from Galafold and lysosomal programs to secure orphan designations and accelerated reviews, where Priority Review shortens FDA review to about 6 months and orphan status grants 7 years US exclusivity, shortening time to market and de‑risking launch.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEstablished HTA\/specialty payer ties improve reimbursement\u003c\/li\u003e\n\u003cli\u003ePatient services and outcomes contracts align value and access\u003c\/li\u003e\n\u003cli\u003eCapabilities create high barriers for newcomers\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient-community engagement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eStrong ties with patient advocacy groups support recruitment, adherence, and real-world evidence generation, complementing Amicus assets such as migalastat, approved in the U.S., EU and Japan. Educational initiatives have raised diagnosis and referral rates in under-recognized lysosomal disorders, while community feedback loops shape trial design and patient-relevant endpoints. This engagement fosters brand trust and long-term loyalty among rare-disease populations.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eadvocacy partners: support recruitment \u0026amp; RWE\u003c\/li\u003e\n\u003cli\u003eeducation: raises diagnosis\/referral in rare diseases\u003c\/li\u003e\n\u003cli\u003efeedback loops: inform trial design \u0026amp; endpoints\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLysosomal expertise and genotype-guided therapy boost payer access and long-term uptake\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAmicus combines deep lysosomal storage expertise with Galafold approved in over 40 countries (FDA approval 2016). Orphan status (US 7 years, EU up to 10) and genotype‑guided prescribing strengthen payer value and access. Patient‑support programs, advocacy ties and RWE registries de‑risk launches and sustain commercial adoption.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGalafold approvals\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;40 countries\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA approval\u003c\/td\u003e\n\u003ctd\u003e2016\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS orphan exclusivity\u003c\/td\u003e\n\u003ctd\u003e7 years\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePriority Review\u003c\/td\u003e\n\u003ctd\u003e~6 months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT overview of Amicus Therapeutics, highlighting its strengths in rare-disease expertise and pipeline innovation, weaknesses like commercialization and financial constraints, opportunities from gene therapy partnerships and orphan drug market expansion, and threats including competition, regulatory hurdles, and reimbursement pressures.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a focused SWOT overview of Amicus Therapeutics to quickly identify strengths, weaknesses, opportunities, and threats, easing strategic prioritization for development and commercialization decisions. Ideal for executives and teams needing a rapid, visual snapshot to align actions and presentations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProduct concentration risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRevenue is heavily concentrated in a few rare-disease therapies, notably GALAFOLD, with company filings through 2024 showing a majority of product receipts tied to those assets. Any safety signal, competitor entry, or reimbursement setback could disproportionately reduce top-line results. This lack of diversification raises earnings volatility and may force investors to demand a higher risk premium.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSmall addressable populations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eInherent rarity (Fabry prevalence ~1:40,000–1:117,000) caps absolute sales even with per‑patient pricing in the ~$200k–$300k\/yr range for therapies like migalastat. Growth thus hinges on expanded diagnosis and geographic rollout. Mature markets can saturate rapidly as diagnosed cohorts are treated. This limits operating leverage and long‑term margin expansion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and supply complexity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBiologic and specialty small-molecule supply chains for Amicus require stringent quality controls, and any disruption can impede patient continuity and strain payer relationships. Reliance on third-party CDMOs means tech transfers and scale-up carry execution risk, while redundancy and inventory buffers materially raise COGS and working capital needs. Manufacturing complexity increases time-to-market and reimbursement pressure.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReimbursement sensitivity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eHigh-cost therapies face rigorous payer scrutiny and tight utilization management, constraining formulary placement and access. Coverage decision delays often slow real-world uptake after approval, increasing commercialization risk. Continuous generation and updating of outcomes evidence is required to defend value as reimbursement criteria evolve across markets, and cross-country variability complicates forecasting.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003epayer scrutiny\u003c\/li\u003e\n\u003cli\u003ecoverage delays\u003c\/li\u003e\n\u003cli\u003eevidence refresh need\u003c\/li\u003e\n\u003cli\u003ecountry variability\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical development risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRare-disease trials for Amicus are typically small and endpoint-sensitive, often enrolling under 100 patients, making outcomes volatile; Galafold was approved in 2018 but pipeline value can collapse quickly on negative or equivocal readouts. Post-marketing commitments for approved therapies add recurring cost and regulatory risk, while emerging gene therapies and shifting standards of care can change commercial assumptions mid-development.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSmall trial sizes (\u0026lt;100) increase variability\u003c\/li\u003e\n\u003cli\u003eNegative\/equivocal data can rapidly reduce pipeline value\u003c\/li\u003e\n\u003cli\u003ePost-marketing commitments create ongoing costs\u003c\/li\u003e\n\u003cli\u003eShifting standards of care (gene therapies) threaten assumptions\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFabry revenue concentration, small trials and pricing caps elevate risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRevenue is concentrated in a few rare‑disease therapies (company filings through 2024 show a majority of product receipts tied to GALAFOLD), creating high top‑line sensitivity to safety, competition, or reimbursement setbacks. Fabry prevalence (~1:40,000–1:117,000) and migalastat pricing (~$200k–$300k\/yr) cap market size. Small trials (\u0026lt;100) and post‑marketing obligations raise regulatory and pipeline volatility.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 product concentration\u003c\/td\u003e\n\u003ctd\u003eMajority tied to GALAFOLD\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFabry prevalence\u003c\/td\u003e\n\u003ctd\u003e1:40,000–1:117,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMigalastat price\u003c\/td\u003e\n\u003ctd\u003e$200k–$300k\/yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTypical trial size\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;100 patients\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eSame Document Delivered\u003c\/span\u003e\u003cbr\u003eAmicus Therapeutics SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual Amicus Therapeutics SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full SWOT report you'll get; purchase unlocks the entire in-depth, editable version. You’re viewing a live excerpt of the real file, structured and ready to use after checkout.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eO\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003epportunities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLabel expansions and new indications\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLifecycle management across adjacent GLA mutations and phenotypes can extend revenue duration for Galafold, originally approved in the US in 2018; Fabry disease affects roughly 1:40,000 to 1:117,000 individuals, leaving room for label growth. Pediatric or early-onset and combination-therapy trials could broaden eligibility, while biomarker-guided subgroups may raise responder rates and incremental approvals can leverage Amicus’s existing commercial and manufacturing infrastructure.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeographic expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFurther penetration into ex-US markets could expand Amicus’ addressable rare-disease population within the WHO-estimated 300 million people living with rare diseases; Galafold is already approved in 40+ countries, showing international uptake. Tailored access strategies are needed to navigate diverse HTA requirements; partnerships or local distributors can accelerate entry into emerging markets, while local real-world data will bolster pricing dossiers and renewal negotiations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiagnostic and newborn screening adoption\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRising uptake of genetic and newborn screening—which in the US already covers over 98% of newborns—boosts identification of eligible patients for Amicus programs. Collaboration with diagnostic labs and payers can streamline test-to-treat workflows and reimbursement. Earlier diagnosis, evidenced by RUSP additions like Pompe (2015) and MPS I (2016), improves outcomes and extends treatment windows. Screening advocacy can structurally enlarge the addressable market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic collaborations and BD\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIn-licensing complementary assets lets Amicus diversify its rare-disease pipeline efficiently while leveraging its approved small-molecule migalastat (Galafold), approved in the EU (2016) and US (2018). Co-development partnerships share clinical and commercial risk and broaden modalities beyond chaperones into gene and mRNA approaches. Commercial co-promotes and alliances accelerate geographic reach and entry into new rare-disease segments.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eIn-license: diversify pipeline\u003c\/li\u003e\n\u003cli\u003eCo-dev: risk-share, broaden modalities\u003c\/li\u003e\n\u003cli\u003eCo-promote: extend geography\u003c\/li\u003e\n\u003cli\u003eAlliances: faster entry into rare segments\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNext-gen formulations and delivery\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNext-gen formulations improving dosing convenience and tolerability can boost adherence and persistence; long-acting or combo approaches showed 20–30% adherence gains in 2020–24 studies. Device or digital adherence tools increased adherence ~10%, strengthening differentiation. Such enhancements support premium pricing (roughly 10–15% uplifts) and help defend market share in orphan\/metabolic segments.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAdherence gains 20–30% (2020–24 studies)\u003c\/li\u003e\n\u003cli\u003eDigital\/device adherence +~10%\u003c\/li\u003e\n\u003cli\u003ePotential premium pricing 10–15%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLifecycle and label expansion to capture more Fabry patients via screening and partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLifecycle management and label expansion for Galafold can capture additional Fabry patients (prevalence ~1:40,000–1:117,000) and leverage existing commercial\/manufacturing reach (Galafold approved in 40+ countries).\u003c\/p\u003e\n\u003cp\u003eBroader newborn\/genetic screening (US coverage \u0026gt;98%) and biomarker-guided trials enlarge treatable cohorts; in-licensing and co-development diversify modalities and share risk.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eOpportunity\u003c\/th\u003e\n\u003cth\u003eKey data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRare-disease pool\u003c\/td\u003e\n\u003ctd\u003eWHO: ~300M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFabry prevalence\u003c\/td\u003e\n\u003ctd\u003e1:40,000–1:117,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNewborn screening\u003c\/td\u003e\n\u003ctd\u003eUS \u0026gt;98%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdherence gains\u003c\/td\u003e\n\u003ctd\u003e20–30% (2020–24)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eT\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehreats\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntensifying competition\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEstablished enzyme replacement therapies such as Sanofi\/Genzyme’s Fabrazyme and Myozyme and emerging gene and substrate reduction modalities increasingly compete with Amicus in Fabry and Pompe, raising risk of patient switches if rivals demonstrate superior efficacy or convenience. Aggressive competitor pricing and rebate strategies threaten net realized prices and payer coverage. High-profile rival pipeline readouts in 2024–25 have reset expectations for standards of care.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePricing and policy pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGlobal scrutiny of orphan-drug pricing raises real risk of price cuts, clawbacks or tighter coverage that could reduce peak revenues for Amicus. Reference-pricing and value-based reimbursement frameworks increasingly cap upside, limiting list price growth. U.S. policy shifts and the EU HTA Regulation (entered into application January 2025) centralize assessments and can toughen negotiations, elongating time-to-revenue and compressing margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and safety risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAs of 2024 Amicus's commercial footprint centers on Galafold, so label changes, REMS or post‑marketing safety findings could materially shrink the eligible patient pool. Manufacturing observations or agency inspections have delayed biologic launches industrywide and could push Amicus key launches beyond planned timelines. Divergent regulator expectations across US, EU and Japan add filing complexity. Any safety event can rapidly erode physician trust and sales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupply chain disruptions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eSingle-source components and specialized manufacturing reduce Amicus Therapeutics resilience; external shocks (e.g., 2020–24 pandemic waves) can interrupt continuity of care and trigger regulatory or payer penalties that impair revenue timing. Freight, cold-chain and API constraints elevate COGS and logistics spend, with the global pharma cold-chain market ~22.5 billion in 2023 highlighting stress on capacity. Recovery timelines are unpredictable and can destroy value through delayed launches and missed milestones.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSingle-source risk: manufacturing concentration\u003c\/li\u003e\n\u003cli\u003eContinuity: external shocks → penalties, delayed care\u003c\/li\u003e\n\u003cli\u003eLogistics: cold-chain capacity strain (~$22.5B pharma market 2023)\u003c\/li\u003e\n\u003cli\u003eRecovery: unpredictable timelines, value erosion\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIP and litigation exposure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePatent challenges and Orange Book disputes threaten Amicus’s long-term cash flows as competitors pursue design-arounds and ANDA litigation; patent defense can span 3–7 years and divert R\u0026amp;D and legal resources. Loss of exclusivity typically drives price erosion up to 80% in year one, accelerating revenue and share declines and increasing forecast uncertainty. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePatent challenges: ongoing risk\u003c\/li\u003e\n\u003cli\u003eDesign-arounds: competitive pressure\u003c\/li\u003e\n\u003cli\u003eLitigation timelines: 3–7 years\u003c\/li\u003e\n\u003cli\u003ePrice erosion: up to 80% year one\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eERTs, gene\/substrate rivals plus EU HTA and payer pressure squeeze pricing and margins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRival ERTs, gene and substrate-reduction programs threaten market share; 2024–25 readouts reset standards. Payer pricing pressure and EU HTA (in force Jan 2025) tighten reimbursement. Cold‑chain costs strain margins (pharma cold‑chain ~$22.5B 2023). Patent loss can cut revenues ~80% in year one; litigation ties up 3–7 years.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eThreat\u003c\/th\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitive readouts\u003c\/td\u003e\n\u003ctd\u003e2024–25 pipeline events\u003c\/td\u003e\n\u003ctd\u003eShare loss\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReimbursement\u003c\/td\u003e\n\u003ctd\u003eEU HTA Jan 2025\u003c\/td\u003e\n\u003ctd\u003ePrice caps\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLogistics\u003c\/td\u003e\n\u003ctd\u003e$22.5B cold‑chain (2023)\u003c\/td\u003e\n\u003ctd\u003e↑COGS\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIP\u003c\/td\u003e\n\u003ctd\u003e80% price drop yr1\u003c\/td\u003e\n\u003ctd\u003eRevenue collapse\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"PESTEL Analysis","offers":[{"title":"Default Title","offer_id":58098032607580,"sku":"amicusrx-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0938\/8127\/0620\/files\/amicusrx-swot-analysis.png?v=1781788151","url":"https:\/\/pestel-analysis.com\/products\/amicusrx-swot-analysis","provider":"PESTEL ANALYSIS","version":"1.0","type":"link"}